Clinical Trial

Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma

Study acronym: TACE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Trans-arterial chemoembolization (TACE) is a standard treatment for patients with hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected into the arteries of the liver and liver cancer. Unfortunately, the tumour grows after TACE in many patients. A new treatment using a specialized radiation procedure called Stereotactic ablative body radiotherapy (SBRT) may increase the chance to control liver cancer. SBRT allows radiation treatments to be focused more precisely, and be delivered more accurately than with older treatments. The purpose of this study is to find out if TACE alone versus TACE plus SBRT is better for you and your liver cancer.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-03-27; most recent amendment 2025-03-07.
Status change: Withdrawn → Recruiting 2021-11-10
Status change: Recruiting → Withdrawn 2021-01-23
Status change: Not Yet Recruiting → Recruiting 2019-07-23
Trial Details
NCT Number NCT03895359
Lead Sponsor London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Collaborators: CancerCare Manitoba
Conditions Hepatocellular Carcinoma
Enrollment 128 participants
Start Date 2019-05-27
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-11